Blood Cancer clinical trials

Explore recruiting blood cancer clinical trials.

Recruiting blood cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Blood Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib plus Chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)

Sweden, Finland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 1/2a, first-in-human, open-label, multicenter, dose escalation study of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

France, Netherlands, Lithuania

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Spain, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

Denmark, Sweden, Czechia, Belgium, Hungary, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219

Spain, Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Blood Cancer trials by city

Blood Cancer in Toronto Blood Cancer in Vancouver Blood Cancer in Montreal Blood Cancer in Calgary Blood Cancer in Edmonton Blood Cancer in Ottawa Blood Cancer in Winnipeg Blood Cancer in Quebec City Blood Cancer in Hamilton Blood Cancer in Kitchener Blood Cancer in London Blood Cancer in Halifax Blood Cancer in New York Blood Cancer in Los Angeles Blood Cancer in Chicago Blood Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease